Deciphera Pharmaceuticals, Inc.’s Quiet Period To Expire on November 7th (NASDAQ:DCPH)

Deciphera Pharmaceuticals’ (NASDAQ:DCPH) quiet period is set to end on Tuesday, November 7th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its public offering on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Several research firms have recently weighed in on DCPH. Nomura began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target on the stock. Piper Jaffray Companies began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 target price on the stock. Instinet began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $57.00 target price on the stock. JMP Securities began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “outperform” rating and a $38.00 target price on the stock. Finally, J P Morgan Chase & Co began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “overweight” rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $43.40.

WARNING: “Deciphera Pharmaceuticals, Inc.’s Quiet Period To Expire on November 7th (NASDAQ:DCPH)” was published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://weekherald.com/2017/11/15/deciphera-pharmaceuticals-inc-s-quiet-period-set-to-end-tomorrow-nasdaqdcph.html.

Shares of Deciphera Pharmaceuticals (DCPH) opened at $17.51 on Wednesday. Deciphera Pharmaceuticals has a 12-month low of $16.11 and a 12-month high of $24.50.

In other Deciphera Pharmaceuticals news, major shareholder New Leaf Venture Management Ii acquired 375,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,375,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $1,946,000. Orbimed Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $7,487,000. Alyeska Investment Group L.P. purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $1,968,000. Citadel Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $4,965,000. Finally, FNY Managed Accounts LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $153,000. Institutional investors own 2.58% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply